ImmuneOncia Therapeutics Inc.

Clinical trials sponsored by ImmuneOncia Therapeutics Inc., explained in plain language.

ImmuneOncia Therapeutics Inc. 424870 KOSDAQ

A biotech company developing immunotherapies for cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug IMC-001 targets Hard-to-Treat cancers in small trial Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1

New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients

Disease control Ongoing

This study tests an experimental drug called IMC-001 in 23 adults with a rare lymphoma (NK/T-cell) that has returned or stopped responding to prior therapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive IMC-001 and are monito…

Phase 2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

ImmuneOncia Therapeutics Inc.

Upcoming readouts

New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients